With a new generation of weight-loss drugs entering Indian markets, spelling hope for many, The Indian Express tracks the ...

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and fueling a bidding war over another drugmaker.

Eli Lilly (LLY) delivered standout results, with earnings climbing at a 20% annual pace over the past five years and surging 120% in the last year alone. Net profit margins rose to 31% versus 20.5% a ...

Ozempic, Mounjaro and Wegovy are now cultural symbols of weight loss. These medications help control blood sugar and aid ...

Mounjaro arrived in the US in 2022 for diabetes, demonstrating powerful effects on both glucose and weight. Its counterpart, ...

An expert said weight loss drugs might help people see faster results, which can give them encouragement to continue. But he ...

Health-care companies rose amid earnings optimism. Eli Lilly added to gains, amid a sense that the maker of Mounjaro and Zepbound is pulling away from its competition in the obesity-drug boom. Shares ...

As of Wednesday, when the stock rose 3%, Nvidia was larger than Qualcomm, AMD, Arm Holdings, ASML, Broadcom, Intel, Lam ...

Pfizer said on Friday it had filed a lawsuit against Metsera and Novo Nordisk , saying Metsera breached its merger agreement ...

Record performance of its GLP-1 drugs sent shares in Eli Lilly soaring almost 4% after its earnings call on Thursday.

Merck and Eisai announced termination of a phase III trial of pembrolizumab plus lenvatinib (Lenvima) and transarterial chemoembolization (TACE) for unresectable liver cancer after an interim analysis ...

Plus, the Trump administration is expected to release finalized Medicare payment rules for doctors and hospitals as soon as ...